(Q42623314)

English

Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus

scientific article published on November 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

exposure assessment

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Bengt Hamrén

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

K Peter Ohman

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Maria K Svensson

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Mats O Karlsson

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1317-1327

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Factorial design for the development of automated solid-phase extraction in the 96-well format for determination of tesaglitazar, in plasma, by liquid chromatography-mass spectrometry

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Comparison of four basic models of indirect pharmacodynamic responses

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection

1 reference

https://api.crossref.org/works/10.1177%2F0091270011416937

21 January 2018

Identifiers

10.1177/0091270011416937

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42623314&oldid=2144099158"